anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Source Note

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 110,355
Current window 75,421-75,450
Pages 3,679
Rows per page 30
Component: Source Noteclear collectionreset all
18 30 60

Component

75,421-75,450 of 110,355

filter-aware
30
The slide uses a stylized area chart to represent market segments and their respective valuations.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
32
The table uses a cross-trial comparison format. The red dashed box highlights the key clinical data rows.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
33
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
34
The slide uses a side-by-side comparison of two disease indications, each with a list of clinical outcomes and a bottom section showing relevant market competitors and patient incidence numbers.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
36
Includes a complex biological pathway diagram and three supporting charts (penetration depth, accumulation over time, and apoptosis efficacy).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
40
The slide uses a step-wise process diagram to illustrate dose escalation.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
42
The slide highlights specific safety data points for Arcellx's product, likely for competitive benchmarking purposes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
43
Immix Biopharma | Investor Presentation Deck | 62 slidesImmix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
44
The table compares clinical trial inclusion criteria across four different therapies, focusing on prior lines of therapy, toxicity recovery, ECOG status, and measurable disease definitions.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
45
The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
46
The slide uses a bar chart to contrast the combined market size of two groups of drugs ($33.4bn vs $0.9bn).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
52
The chart on the left is a conceptual visualization rather than a standard data plot, emphasizing the 100% heavily pre-treated patient population.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
54
Includes comparative size illustration of IMX-111 vs IgG antibody, and survival curve data.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
55
Includes two sets of charts: tumor volume over time and survival curves for two different cancer models.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
56
The slide uses a mix of mechanism-of-action diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
58
The slide uses a side-by-side comparison structure to explain two distinct but complementary proprietary platforms.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
59
The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
60
The process flow is non-linear, moving left-to-right on the top row (1-5) and right-to-left on the bottom row (6-10).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
09
The slide uses a background map graphic and a large metric to establish market authority.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations Loop · Golden Circle1 hit
39
Uses a stacked bar chart to visualize the 'dollar gap' between ad spend allocation and consumer time spent.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
48
The slide uses a comparison structure to link client needs (RFP drivers) to the vendor's value proposition (Why We Won).Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
66
Chart shows pro forma revenue including TVS acquisition; CAGR calculated using top end of 2023 guidance.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations Beat · Business Model1 hit
69
The chart uses a dual-axis approach to show revenue growth and expense efficiency over time.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations Beat · Business Model1 hit
70
Includes non-GAAP financial measure disclaimer.Innovid | Investor Day Presentation Deck | 74 slides · Innovid
Conference presentation Investor relations 1 hit
07
Kering | ESG Presentation Deck | 80 slidesKering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Call to Adventure1 hit
09
The slide uses a stakeholder-based value distribution framework.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Call to Adventure1 hit
13
The slide uses a hub-and-spoke diagram to show ownership percentages relative to Kering.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
15
The data highlights the evolution of board governance metrics over a 13-year period.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
16
The slide uses a dual-visualization approach: a horizontal bar chart for total counts and a dot matrix for individual director skill mapping.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
17
The slide uses icons to categorize each governance practice.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit